SMi logo

+44 (0)20 7827 6000

events@smi-online.co.uk

Basket Total: £0.00

Defence, Security, Energy, Utilities, Finance, Pharmaceuticals

Home > Pharmaceuticals > UK

Pharmaceutical Nanotechnology: Applications & Commercialisation

29th June to 30th June 2011, London, United Kingdom

Buy Now

Buy Now Programme

Programme

Expand all Timeslots

Collapse all Timeslots

8.30		Registration & Coffee
9.00		Chairman's Opening Remarks Mike Eaton, Executive Board Member, European Technology Platform on Nanomedicines View Bio
9.10		Nanotechnology in Pharma industry Deepak Murpani, Vice President, Product Development, Genepharm View Bio Applications/ Advantages Review of existing nanotechnologies Opportunities/ Technical challenges Converting challenges to opportunities using right technology Reaping benefits of Nanotechnology as a Brand company Creating new opportunities for Generic/ Supergeneric company Case studies Future potential of Nano in Pharma
9.45		Nanoscale drug delivery systems Giancarlo Francese, Project Leader, Pharmaceutical Development, Novartis Role of nanotechnology in targeted drug delivery Evaluating the available technologies Performance and safety issues Case study: The development of biodegradable nanoscale drug delivery systems at Novartis Looking ahead to future steps in pharmaceutical development
10.20		Morning Coffee
11.25		Miniaturisation and modelling of beads milling Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D View Bio Relevant information to get at lab scale in order to help the scale-ability Is it possible to apply similar methodology to that developed for dry milling-micronisation? Impact of process parameters and formulation on milling performances
12.00		Ten development criteria to cross barriers from blood-to-brain using nanotechnology Marco de Boer, Head of Research, to-BBB technologies BV View Bio Success criteria based on: 1) safely targeting the blood-brain barrier; 2) use of validated drug carriers; 3) translation from lab to clinic Introduction to G-Technology Case study I: glutathione pegylated liposomal doxorubicin (2B3-101) for brain cancer Case study II: pharma industry partnering model
12.35		Delivering peptides to the brain Ijeoma Uchegbu, Scientific Secretary CRS, Chair in Pharmaceutical Nanoscience, University Of London View Bio The challenge Nanoparticle/ nanofibre technology Delivering peptides via the intravenous route Delivering peptides via the oral route Case study: Oral Enkephalin
13.10		Networking Lunch
14.10		New nanomaterials for regenerative medicine Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine, Imperial College London View Bio Materials based approaches for regenerative medicine Design of nanomaterial scaffolds for tissue regeneration Translation to commercial products and clinical studies
14.45		Nanoparticles for the delivery of oligonucleotides targeting EWS/Fli-1 Claude Paul Malvy, Director, IFSBM, Universite Paris Sud View Bio The prevalence of EWS/Fli-1 oncogene in Ewing sarcoma patients The need to protect antisense oligonucleotides and siRNA until they reach their EWS/Fli-1 mRNA target Biodegradable and biocompatible polyalkylcyanoacrylate nanoparticles coated with chitozan Developing cationic nanodiamond vectors and evaluating their efficiency for anionic siRNA delivery
15.20		Afternoon Tea
15.55		Delivering siRNA therapeutics Sergey Pechenov, Research Fellow, siRNA Therapeutics, Merck & Co., Inc. View Bio Technology and therapeutic updates Pros and cons of RNAi delivery methods Case study: Lipid nanoparticle-mediated systemic delivery of siRNA to the liver
16.30		Investigation of chitosan nanoparticle formulations Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis Pharma View Bio Impact of chitosan purity, size and source on nanoparticle formulation Biophysical characterization of chitosan/siRNA nanoparticles using dynamic light scattering, zeta potential, isothermal titration calorimetry Cellular trafficking events of siRNA; the role of chitosan polymer size Structure/activity relationships between nanoparticles made of different chitosan polymer sizes
17.05		Chairman’s Closing Remarks and Close of Day One

8.30		Registration & Coffee
9.00		Chairman's Opening Remarks Thomas Keller, Director, Open Innovation, GlaxoSmithKline View Bio
9.10		The business case for nanotechnology Thomas Keller, Director, Open Innovation, GlaxoSmithKline View Bio Limitations and cost effectiveness comparisons Benchmarking and the need for agreed industry standard systems for evaluation Challenges in translational development Partnering strategies and opportunities
9.45		Enabling oncology drug development with nanotechnology Henry Havel, Senior Research Fellow, Product Research and Development, Eli Lilly And Company View Bio Key challenges in oncology drug discovery Optimizing the discovery/development interface Key technology platforms Taking a portfolio approach The Nanomedicines Alliance -- a pre-competitive consortium for cross-industry collaboration
10.20		Morning Coffee
10.50		Improving translation of academic nanomedicine research Mike Eaton, Executive Board Member, European Technology Platform on Nanomedicines View Bio Companies are increasing relying on Open Innovation for new products Academic pharmaceutical research is not informed on the requirements for industrial development Funding agencies continue to fund non-translatable applied research There is now global competition How can the system be made much more productive?
11.25		Building a diversified nanomedicine company Christopher Anzalone, CEO, Calando Pharmaceuticals Balancing diversification and focus Follow the science Models that maximize shots on goal Finding and relying on synergy Case Study: Nanotope, Inc
12.00		Networking Lunch
13.00		Regulatory challenges for nanomedicines Peter Bogaert, Managing Partner, Covington & Burling Brian Kelly, Associate, Covington & Burling Llp View Bio Borderline and classification issues Limitations of current testing methods Development, manufacture and characterisation Risk management planning Reimbursement Public perception Lessons from other sectors Borderline and classification issues Limitations of current testing methods Development, manufacture and characterisation Risk management planning Reimbursement Public perception Lessons from other sectors
13.35		Regulatory considerations of Nanomedicines Ashish Kohli, Assessment Unit Manager, Cardiovascular and Diabetes Products, MHRA View Bio Defining nanomedicines Key challenges for a regulator in the assessment of these products Experience to date
14.10		A tour of today's Nanomedicine patent landscape: predicting where the future IP battle lines will be drawn Jeffrey Rosedale, Partner, Woodcock Washburn LLP The current patent landscape of nanotech-enabled pharmaceutical applications The expectation that the commercialization of nanotech-enabled pharmaceuticals will lead to patent battles of epic proportions Predictions of the most likely IP battlegrounds and of those who are battling
14.45		Drug Delivery and Nanostructuring: Divergent Effects Paul Ashton, President & CEO, pSivida View Bio BioSilicon Technology: Stabilization of amorphous forms. Enhanced dissolution and bioavailability of poorly soluble molecules Tethadur Systems: Protein adsorption Sustained release of Anti-Bodies BioSilicon Technology: Stabilization of amorphous forms. Enhanced dissolution and bioavailability of poorly soluble molecules Tethadur Systems: Protein adsorption Sustained release of Anti-Bodies
15.20		Chairman’s Closing Remarks and Close of Day Two
15.30		Afternoon Tea

Conference Documentation

Order Conference Documentation / Further Enquiries

Share This Event

Sponsors

Sponsors to be confirmed - For sponsorship and exhibition opportunities please contact sponsorshipdept@smi-online.co.uk or click here.

Contact Details

UK Office
Local Time Now:
Opening Hours: 9.00 - 17.30 (local time)
Tel: +44 (0) 20 7827 6000
Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk
Email: events@smi-online.co.uk

CPD

SMi is a member of the CPD service

World Courier